Q-omics provides the consensus-scored LINC01356 profile across patient tissues and cancer cell-line models. LINC01356 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC01356 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, LINC01356 RNA expression shows 11,194 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight UVM, HNSC, and BLCA as cancer lineages where LINC01356 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01356 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01356 survival associations across molecular data types. LINC01356 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01356 RNA expression–survival associations across cancer types. High LINC01356 expression shows unfavorable associations in HNSC, UCEC, COAD, UCS and LUSC, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC01356 RNA expression.
This table summarizes LINC01356 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01356. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01356 shows higher tumor expression in HNSC, COAD, THCA, KIRC, KIRP and STAD. The HNSC box plot shows higher LINC01356 RNA expression in tumor versus normal tissue (log2 FC = +0.460, t-test p < 0.001).
This table shows molecular features associated with LINC01356 in patient tissues and cancer cell lines. In patient samples, LINC01356 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set.
